Clinical trials for Lymphoma

101 currently recruiting clinical trials
Phase 1 / Phase 2 Lymphoma #NCT06137144
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Lymphoma #NCT06137144
Required histologic types
Hodgkin lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
None
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Lymphoma #NCT06137144
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Immunotherapy Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Lymphoma #NCT06137144
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required disease stage
Disseminated (stage III and IV)
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Lymphoma #NCT04502394
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
TP53
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2 Lymphoma #NCT06697184 #2024-518829-15-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
BeOne Medecines
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome Acute leukemia Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT07220616 #2025-522595-87-00
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
3 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Lymphoma #NCT04104776 #2023-508002-20-00
Required histologic types
B cell lymphoma T cell lymphoma
Required histologic sub types
Large B cell lymphoma Peripheral T cell lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive Allogeneic stem cell transplant
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Lymphoma #NCT06090539
Required histologic types
B cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
7 recruiting sites
Bristol-Myers Squibb
Phase 1 / Phase 2 Lymphoma #NCT06564038 #2024-515034-33-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required disease stage
Early (stage I and II) Disseminated (stage III and IV)
Required number of previous lines of therapy
2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
AstraZeneca